Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200026/S018

Abre Venous Self-expanding Stent System

Medtronic Vascular, Inc. · Decision date Apr 27, 2026

FDA DECISIONP200026/S018

What did the FDA decide?

FDA records P200026/S018 as a supplement to PMA P200026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 27, 2026.

FDA approval order statement

removal of the stent filing process step
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Apr 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200026/S018
Regulatory pathway
PMA supplement
Product code
QAN
Decision code
OK30
Decision date
Apr 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, iliac vein.

Product code
QAN
FDA device class
3

For the original device and its historical approval scope, see PMA P200026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200026 · Original PMA

    Abre Venous Self-expanding Stent System

  2. P200026/S014 · Related supplement

    Abre Venous Self-expanding Stent System

  3. P200026/S015 · Related supplement

    Abre Venous Self-expanding Stent System

  4. P200026/S016 · Related supplement

    Abre Venous Self-expanding Stent System

  5. P200026/S018 received

    Application receipt date recorded by FDA.

  6. P200026/S017 · Related supplement

    Abre Venous Self-expanding Stent System

  7. P200026/S018 · FDA decision

    30-Day Notice

  8. P200026/S019 · Related supplement

    Abre Venous Self-Expanding Stent System

  9. P200026/S020 · Related supplement

    Abre Venous Self-expanding Stent System

Timeline entries are records held by MedtechLedger for P200026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic Vascular, Inc.PMA approvalOct 21, 2020FDA
Medtronic Vascular, Inc.PMA supplementSep 23, 2025FDA
Medtronic Vascular, Inc.PMA supplementDec 12, 2025FDA
Medtronic Vascular, Inc.PMA supplementMar 23, 2026FDA
Medtronic Vascular, Inc.PMA supplementApr 8, 2026FDA
Medtronic Vascular, Inc.PMA supplementOct 16, 2026FDA
Medtronic Vascular, Inc.PMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code QAN

Product / regulatory recordCompanyPathwayDecision dateSource
Philips Image Guided Therapy CorporationPMA supplementAug 26, 2026FDA
Bard Peripheral Vascular, Inc.PMA supplementJun 10, 2026FDA
Cook Ireland, Ltd.PMA supplementApr 14, 2026FDA
Philips Image Guided Therapy CorporationPMA supplementFeb 12, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3033 Campus Dr., Plymouth, MN, 55441

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records